Bleakley Financial Group LLC Acquires 9,208 Shares of Danaher Corporation $DHR

Bleakley Financial Group LLC increased its holdings in Danaher Corporation (NYSE:DHR) by 34.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,709 shares of the conglomerate’s stock after acquiring an additional 9,208 shares during the period. Bleakley Financial Group LLC’s holdings in Danaher were worth $8,175,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. JPL Wealth Management LLC bought a new position in shares of Danaher in the third quarter valued at approximately $25,000. Elevated Capital Advisors LLC bought a new position in shares of Danaher in the fourth quarter valued at approximately $26,000. WFA of San Diego LLC bought a new position in shares of Danaher in the second quarter valued at approximately $26,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Danaher in the third quarter valued at approximately $27,000. Finally, Financial Life Planners bought a new position in shares of Danaher in the third quarter valued at approximately $32,000. 79.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent analyst reports. Rothschild & Co Redburn set a $205.00 target price on Danaher in a report on Friday, April 17th. Wolfe Research reduced their price objective on Danaher from $260.00 to $230.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Morgan Stanley reduced their price objective on Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a report on Wednesday, April 22nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Danaher in a report on Thursday, January 29th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $245.00 price objective on shares of Danaher in a report on Tuesday, April 21st. Nineteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $238.65.

Danaher Price Performance

Shares of NYSE DHR opened at $172.12 on Tuesday. The stock has a fifty day simple moving average of $183.23 and a two-hundred day simple moving average of $208.40. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The firm has a market cap of $121.82 billion, a price-to-earnings ratio of 33.29, a price-to-earnings-growth ratio of 2.30 and a beta of 0.81. The company has a current ratio of 1.87, a quick ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business’s quarterly revenue was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.88 earnings per share. Analysts anticipate that Danaher Corporation will post 8.43 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a dividend of $0.40 per share. The ex-dividend date is Friday, June 26th. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. Danaher’s dividend payout ratio is currently 30.95%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.